Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07052942 · ClinicalTrials.gov registry record · Phase 4
Individualizing Treatment for Asthma in Primary Care (Full Study)
A Phase 4 study of Asthma and Asthma Attack, sponsored by DARTNet Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3,200
- Enrollment target
- 13
- Study locations
NCT07052942 is a Phase 4 study of Asthma and Asthma Attack that is actively recruiting participants, run by DARTNet Institute. The registered enrollment target is 3,200 participants, above the 1,555-participant average among 374 other Asthma trials with a reported enrollment target (106% higher). The trial reports 13 study locations across 10 states.
The verdict
NCT07052942, a Phase 4 study of Asthma and Asthma Attack, is actively recruiting participants, sponsored by DARTNet Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,200 participants
- Enrollment target
- 13
- Study locations
Study Summary
While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Inhaled corticosteroid (ICS)
- OTHER Asthma Symptom Monitoring Web-based Application
Study Locations (13)
Colorado
- DARTNet Institute - Aurora
- University Colorado-Denver - Aurora
North Carolina
- University North Carolina - Chapel Hill
- Atrium Health - Charlotte
Texas
- JPS Health Network - Fort Worth
- Kelsey Research Foundation - Houston
Florida
- AdventHealth - Orlando
Kansas
- University of Kansas - Kansas City
Massachusetts
- Reliant Medical Group - Worcester
Missouri
- University of Missouri - Columbia
New Jersey
- Rutgers Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2029-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07052942
The ClinicalTrials.gov registry entry for NCT07052942 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 3,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,555-participant average among 374 other Asthma trials with a reported enrollment target (106% higher). The listed sponsor is DARTNet Institute, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Azithromycin is the first listed.
NCT07052942 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Colorado, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07052942 about?
NCT07052942 is a clinical study titled "Individualizing Treatment for Asthma in Primary Care (Full Study)". While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long ...
What is the current status of trial NCT07052942?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,200 participants. The study started on 2025-08-01. Estimated completion is 2029-11-15.
What conditions does trial NCT07052942 study?
This clinical trial studies the following conditions: Asthma, Asthma Attack, Asthma Exacerbations.
What interventions are being tested in trial NCT07052942?
The interventions under investigation include: Azithromycin (DRUG), Inhaled corticosteroid (ICS) (DRUG), Asthma Symptom Monitoring Web-based Application (OTHER).
Who is sponsoring clinical trial NCT07052942?
This trial is sponsored by DARTNet Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07052942 being conducted?
This trial has 13 study locations across Colorado, Florida, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.